Over the last several years, mesenchymal stromal cells (MSCs) have been isolated from different tissues following a variety of different procedures. Here, we comparatively assess the ex vivo and in vivo properties of MSCs isolated from either adipose tissue or bone marrow by different purification protocols. After MSC transplantation into a mouse model of hindlimb ischemia, clinical and histological analysis revealed that bone marrow MSCs purified on adhesive substrates exerted the best therapeutic activity, preserving tissue viability and promoting formation of new arterioles without directly transdifferentiating into vascular cells. In keeping with these observations, these cells abundantly expressed cytokines involved in vessel maturation and cell retention. These findings indicate that the choice of MSC source and purification protocol is critical in determining the therapeutic potential of these cells and warrant the standardization of an optimal MSC isolation procedure in order to select the best conditions to move forward to more effective clinical experimentation.
INTRODUCTION
Mesenchymal stromal cells (MSCs) are defined as multipotent, self-renewing cells residing in several tissues, including the bone marrow, adipose tissue, umbilical cord blood, and placenta (Pittenger et al., 1999) . These cells are defined as multipotent, as they are capable of generating different mesenchymal cell types, traditionally adipocytes, chondrocytes, and osteocytes, but also smooth muscle cells and cardiomyocytes (Makino et al., 1999; Pittenger et al., 1999) . MSCs have been at the forefront of clinical research for the therapy of cardiovascular disorders for many years. In particular, cardiac and peripheral ischemia is a leading cause of morbidity and mortality in our aging society and suffers from a lack of curative therapies (Tendera et al., 2011) . In this setting, MSC transplantation has been proposed as an innovative therapy for no-option ischemic patients. Originally, the therapeutic potential of these cells was thought to arise through their putative capacity to transdifferentiate, thereby directly contributing to vasculogenesis and tissue regeneration (Quevedo et al., 2009 ). This attractive hypothesis led to the prompt, perhaps immature transition of the results obtained in animal models to the clinics, with the ambitious goal to regenerate ischemic tissues (Hare et al., 2009; TateishiYuyama et al., 2002) . However, MSC plasticity has been later harshly questioned (Noiseux et al., 2006) , and the therapeutic potential of these cells is currently considered to derive from the secretion of a variety of growth factors and cytokines exerting a paracrine, protective effect on ischemic cells (Gnecchi et al., 2012) .
Despite the common definition of MSCs and the modest but real therapeutic effect exerted by these cells in various experimental and clinical settings, there is no universal agreement on the optimal source and method for MSC isolation and culture (Soleimani and Nadri, 2009; Sung et al., 2008; Yamamoto et al., 2007) . This importantly limits the possible comparison of the observed results in terms of MSC characterization and therapeutic activity. Most of the studies that compared different MSC types are based on the analysis of surface markers, multipotency, and angiogenic assays ex vivo (Lee et al., 2004; Peng et al., 2008) . A few studies also compared MSC activity in vivo, in animal models of cardiac and limb ischemia, but they considered either different tissue sources (van der Bogt et al., 2009) or different purification methods (Seeger et al., 2007) and never the combination of the two parameters. Additional relevant variables in these studies are the species from which MSCs were isolated and the specific animal model used to ascertain their therapeutic properties. This again prevents the direct comparison of most of the existing studies and warrants the prospective characterization of MSCs derived from various tissues and purified according to different purification protocols.
Here, we provide evidence that murine MSCs, harvested from either adipose tissue or bone marrow and following different purification procedures, behave differently and, most importantly, exhibit different therapeutic potential in a mouse model of critical limb ischemia (CLI). This underlines the need to adopt optimal and standardized methods for MSC processing in future preclinical and clinical trials.
RESULTS

MSCs Isolated from Different Sources and according to Different Procedures Show a Common Phenotype
To identify the optimal population of MSCs to treat hindlimb ischemia, cells were purified from either the adipose tissue or the bone marrow of mice using three different protocols. Adipose tissue (AT) MSCs were isolated by tissue digestion followed by centrifugation, while bone marrow (BM)-derived MSCs were obtained by either frequent medium changes (BM-MSCs) or immunodepletion (iBM-MSCs) ( Figure 1A ). In all three cases, the first MSC colonies appeared after a few days and cells were cultured until they reached 80% confluence (within 10 days for AT-MSCs and 6 weeks for both types of BM-derived cells). When assessing their proliferative potential, iBM-MSCs appeared to grow significantly faster than the other populations ( Figure 1B) . When seeded at a low number, all three MSC cell types formed a similar number of colonies, confirming their clonogenic potential ( Figures  1C and 1D ). Despite their high proliferative capacity, MSCs did not become immortal but started to express the senescence-associated b-galactosidase (SAbgal) marker at passage 12 (Figure S1A available online) and stopped multiplying after an additional three to six passages.
Regardless of their different origin and isolation protocol, the three cell populations exhibited a very similar marker profile. They abundantly expressed the MSC-defining CD44, CD105, CD29, and CD90 markers, whereas they scored negative for endothelial (CD31), myeloid (CD11b, GR-1), or hematopoietic (CD45 and CD34) antigens (Boxall and Jones, 2012) . Low levels of expression were also found for SCA-1, c-KIT, TIE-2, CXCR4, and TER-119 (Figures 1E and S1B; Table S1 ).
Finally, AT-MSCs, iBM-MSCs, and BM-MSCs were probed for their capacity to differentiate into adipocytes, chondrocytes, and osteocytes. Adipogenic medium induced the appearance of lipid vacuoles, positive to oil red staining; chondrogenic medium forced the cells to accumulate alcian blue-positive proteoglycans; and osteogenic medium dramatically induced accumulation of intracellular calcium deposits, reactive to Alizarin staining ( Figure 1F ). These results confirm the multipotency of the three MSC populations.
Transplantation of AT-MSCs, iBM-MSCs, and BMMSCs Markedly Reduces Severe Hindlimb Ischemia
We assessed MSC therapeutic potential in a mouse model of hindlimb ischemia induced by removal of the entire femoral artery. The day following surgery, the animals received 2 3 10 5 cells (or medium as control) in the limb homolateral to ischemia (Figure 2A ). Clinical follow-up over 3 weeks showed a significant improvement in the group injected with iBM-MSCs, but the most significant improvement was seen in the group injected with BM-MSCs ( Figure 2B ). Histological analysis of muscle sections at day 21 showed extensive necrosis, adipose substitution, and marked infiltration by inflammatory cells in control animals. In contrast, the muscles injected with any MSC population showed a statistically significant reduction of the inflammatory infiltrate ( Figures 2C and 2D ), associated with a smaller lesion area (Figures 2C and 2E) . In addition, the number of regenerating fibers, characterized by central nuclei, was significantly higher in animals treated with cells of BM origin, in particular in the case of BM-MSCs ( Figures  2C and 2F ). Thus, postischemic administration of any MSC type, but mostly of BM-MSCs, remarkably improves functional and structural recovery of the ischemic limb.
MSCs Induce Neovascularization in Ischemic Muscles
To assess the angiogenic potential of MSCs, muscles were double labeled with lectin, which stains endothelial and mononuclear cells, and antibodies against a-smooth muscle actin (a-SMA), which marks smooth muscle cells (SMCs) surrounding arterial vessels ( Figure 3A ). Whereas no significant difference in the number of lectin-positive cells was detected, all three MSC populations stimulated a massive formation of 10-100 mm arterioles ( Figure 3B ). This effect was particularly pronounced in the case of BM-MSCs. Lead by recent literature supporting the paracrine activity of MSCs (Gnecchi et al., 2012; Mirotsou et al., 2011) , we analyzed the mRNA levels of a series of molecules involved in blood vessel formation and maturation ( Figure 3C ). BM-MSCs were found to express particularly abundant levels of factors required for vessel stabilization, SMC migration, and matrix remodeling, such as Tgf-b, Pdgf-b, and Mmp9. In addition, these cells also expressed high levels of Ccl5 and Sdf-1a, two chemokines known to be involved in the recruitment and retention of proangiogenic macrophages and MSCs themselves (Abbott et al., 2004; Chen et al., 2008) . Thus MSCs, and in particular BM-MSCs, express a cocktail of soluble factors able to enhance their retention in an autocrine manner and also attract proangiogenic cells. To confirm the latter concept experimentally, we performed a migration assay and found that BM-MSCs were the only cell type able to attract murine SMCs ( Figures 3D and  3E ), similar to 10% fetal bovine serum (used as positive control) and consistent with their abundant expression of Pdgf-b at the mRNA and protein level (Figures 3C and S2) (Gerthoffer, 2007) . The ample production of proangiogenic cytokines by the various MSCs suggested that the same promigratory effect could be achieved by the delivery of their conditioned medium (CM). To explore this possibility, we injected the medium harvested from the same number of AT-MSCs, iBM-MSCs, and BM-MSCs (2 3 10 5 ) used in the previous experiment, at days 1, 3, and 7 after surgery. This treatment resulted in a clear trend toward improvement in all the morphological and functional parameters analyzed ( Figure S3) . (Figures 4 and S4) . In control animals, a large perfusion deficit was evident at day 1 and was still present 2 weeks after ischemia. A statistically significant improvement that was evident starting at day 7 after injection was detected in the animals treated with BMMSCs ( Figures 4B and 4C) . A moderate recovery was detected in iBM-MSC-treated animals at 1 week, while AT-MSCs did not provide any benefit compared to controls. Thus, BM-MSCs were the most effective cells in inducing functional vascularization. We then explored the possible mechanisms responsible for the superior performance of BM-MSCs. We observed that BM-MSCs and AT-MSCs resisted doxorubicin-or hydrogen-peroxide-induced apoptosis more than iBMMSCs, as evaluated by caspase-3/7 activation and Annexin V staining ( Figures 4D and 4E ). When analyzing their persistence into ischemic muscles in vivo, we found that the engraftment of BM-MSCs was significantly higher at day 21 compared to the other two MSC types (Figures 4F and 4G) . To investigate whether these cells directly contributed to the formation of new vessels by transdifferentiation, we evaluated the colocalization of 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI)-labeled MSCs with endothelial (CD31) and SMC (a-SMA) markers. The complete lack of colocalization (Figures 4H and 4I) further supports a paracrine mechanism responsible for their angiogenic properties.
DISCUSSION
This study provides a comparison of the therapeutic properties of three MSC populations isolated from two different tissues (BM and AT) according to different purification protocols. Our results show that (1) the three MSC types acquire similar phenotypic and functional properties after the first passages, (2) any MSC type provides therapeutic benefit after CLI, (3) BM-MSCs perform better than the other types in preserving tissue viability and inducing neovascularization, and (4) BM-MSCs do not transdifferentiate in vivo into vascular structures but persist longer and act in a paracrine manner to promote vascular formation. The first objective of this study was the definition of an optimal protocol for MSC isolation. We intentionally focused on BM and AT, as these are the most accessible tissues for MSC recovery. Current protocols for AT-MSC isolation are almost universally based on tissue digestion; for the BM, instead, we selected the two most frequently used methods, namely isolation based on MSC adhesive properties (BM-MSCs) (Soleimani and Nadri, 2009) and density gradient centrifugation, followed by immunodepletion (iBM-MSCs) (Sung et al., 2008) .
Despite presenting a similar behavior in cell culture, the three MSC types showed a different therapeutic potential once injected in vivo in a CLI model, reducing necrosis and inflammation and stimulating muscle regeneration, although at a different extent. They also prompted the formation of functional arterioles, in accordance with previous reports ( (B) Limb function evaluation at days 2, 7, and 21 after CLI according to the criteria described in Table S2 . (C) Representative hematoxylin-eosin staining of ischemic muscle from untreated and treated animals at day 21. Scale bar represents 100 mm for lower magnification and 10 mm for higher magnification. Interestingly, this was better accomplished by BM-MSCs, which abundantly secreted soluble cytokines involved in vessel remodeling and stabilization (such as PDGF-b) and induced the migration of vascular SMCs. This contradicts the findings of Kim et al., who attributed a higher angiogenic and therapeutic potential to AT-MSCs in comparison to MSCs of BM origin (Kim et al., 2007) . A few differences can explain this discrepancy. First, their BM-MSCs were purified by density gradient centrifugation, while our results clearly indicate that the therapeutic potential strictly depends on the isolation protocol. Second, they transplanted human cells into nude mice, which did not allow for the assessment of the immunemodulatory action of MSCs.
Although multiple evidence points toward vascular endothelial growth factor (Vegf) as the main angiogenic cytokine secreted by MSCs (Kinnaird et al., 2004) , we did not observe significant differences in Vegf expression among the three MSC types. Instead, the major differences occurred in genes involved in SMC recruitment and matrix remodeling (Tgf-b, Pdgf-b, and Mmp9), which are two essential events for the proper maturation of arterial vessels (Zacchigna et al., 2008) . Can this arteriogenic effect be recapitulated by the delivery of the MSC supernatant? Although not reaching statistical significance, probably due to the relatively low number of animals analyzed, the repeated injection of CM from the three MSC types resulted in a trend toward improvement, fully consistent with the results observed upon cell transplantation. This supports the conclusion that the MSC secretome could recapitulate the effect of MSC injection (Ranganath et al., 2012) , but its effectiveness is most likely dampened by the short half-life of its molecules. These results leave at least two open questions. First, CM and MSC transplantation were not performed on the same set of animals, and thus we cannot exclude interanimal variability when comparing the efficacy of the two treatments. Second, we did not investigate whether the injection of higher CM amounts or the administration of more frequent doses would result in a better outcome. An additional reason for the higher therapeutic activity of BM-MSCs could be related to the longer engraftment and survival of the cells in vivo. In any case, it appears important to remark that our MSCs did not become immortalized, as they underwent cellular senescence after passage 12 and we never observed formation of tumor masses during long-term follow-up.
In conclusion, our findings indicate that BM-MSCs are the most effective MSC type to improve perfusion and functional recovery after hindlimb ischemia. In contrast to initial studies supporting MSC plasticity (Quevedo et al., 2009 ), these cells were not able to transdifferentiate into either endothelial cells or SMCs while exerting their effect through a paracrine mechanism.
EXPERIMENTAL PROCEDURES
MSC Culture and In Vivo Experiments
MSCs were isolated from the AT or BM of C57/BL6 mice according to three adapted protocols (Soleimani and Nadri, 2009; Sung et al., 2008; Yamamoto et al., 2007) . Cells (2 3 10 5 ) at passage 3-5 were injected into the hindlimb of syngeneic mice the day following resection of the femoral artery. Mice were monitored clinically and by planar scintigraphy and sacrificed at day 21 for histological analysis. Animal care and treatment were conducted in conformity with institutional guidelines, in compliance with national and international laws and policies (European Economic Community Council Directive 86/609, OJL 358, December 12th, 1987, and UE2010763), after institutional review board approval.
MSC Phenotypic Characterization
MSC-specific surface antigens were analyzed by flow cytometry and immunofluorescence. Clonogenic potential was evaluated upon staining with crystal violet. Differentiation was performed using a dedicated kit from LifeLine Cell Technologies.
Histology and Immunofluorescence
Muscle sections were stained with hematoxylin-eosin to perform morphometric analysis, with fluorescein isothiocyanate (FITC)-conjugated lectin and anti-a-SMA antibodies to stain the vasculature. Cells were labeled with DiI prior injection to track cell engraftment.
Real-Time PCR
Total RNA was extracted using TRIzol and reverse transcribed using hexameric random primers. All the amplifications were performed on a Bio-Rad real-time thermal cycler CFX96 using TaqMan probes (Applied Biosystems).
Migration Assay
Murine SMC migration in response to MSC supernatant was performed using 8 mm transwell supports (Costar, Corning).
Apoptosis Assay
MSC apoptosis was induced by hydrogen peroxide (H 2 O 2 ) or doxorubicin and quantified either by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit (Roche) or by using the CaspaseGlo 3/7 Assay System (Promega).
Statistical Analysis
All in vitro experiments were repeated at least three times and performed including at least three biological replicates. Data are presented as mean and SEM. Comparison within groups was analyzed by ANOVA (followed by Bonferroni post hoc analysis) for the evaluation based on tissue sections. In the case of experiments entailing the follow-up of the same animals over multiple time points, we used repeated-measures ANOVA to analyze statistical significance of the differences between groups over time. p < 0.05 was considered as statistically significant.
Additional details on the experimental procedures used in this work are available in Supplemental Experimental Procedures. 
SUPPLEMENTAL INFORMATION
B.
Limb function evaluation at days 2, 7 and 21 after CLI according to the criteria described in Table S2 .
C.
Representative hematoxylin-eosin staining of ischemic muscles of untreated and treated animals at day 21. Scale bar 100 µm for lower magnification and 10 µm for higher magnification. 
Cxcl10 chemokine (C-X-C motif) ligand 10 NM_021274.1 Mm00445235_m1 All the amplifications were performed using pre-developed assays (Applied Biosystems).
The housekeeping gene Gapdh was used to normalize the results.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Murine mesenchymal stromal cells isolation and culture
Bone marrow
Briefly, by flushing the tibia and femur bone cavity with Dulbecco's modified Eagle's medium-high glucose (DMEM-HG) supplemented with penicillin/streptomycin (P/S, 100 U/mL and 100 g/mL), a cell suspension was obtained and filtered through a 70 µm filter mesh to remove any bone spicule or muscle and cell clump. MSCs were then isolated according to two different protocols.
BM-MSCs were isolated using an adapted protocol, previously published (Soleimani and Nadri, 2009 ). This protocol is based on MSC physical propensity to adhere to plastic substrates and on frequent medium changes to avoid contamination by hematopoietic cells. BM-MSCs were cultured in complete medium (DMEM-HG supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and P/S) and non-adherent cells were removed after 3 hours, followed by fresh complete medium replacement. This step was repeated every 12 hours for 3 days. Cells reached 90% confluence in approximately 2 weeks and were lifted by incubation in 0.5 ml of 0.25% trypsin/1 mM EDTA for 2 minutes at room temperature. Lifted cells were cultured in 25-cm 2 flask until confluence at 37°C in a 5% CO 2 humidified incubator, changing the medium every 3-4 days.
iBM-MSCs isolation was based on a density gradient, followed by immunodepletion of monocytes and granulocytes (Sung et al., 2008) . After bone flushing, cells were suspended in equal amount of DMEM and Hank's Balance Salt Solution (HBSS) and all mononuclear cells (MNCs) were isolated by density-gradient centrifugation using
Histopaque-1077 (Sigma Chemical Co.), according to the manufacturer protocol. MNCs were then immunodepleted of monocytes and granulocytes using anti-CD11b-coupled micromagnetic beads (Miltenyi Biotec.) . The residual cells were cultured in complete medium, as described above. After removal of non-adherent cells after 72-96 hours, adherent cells were harvested by trypsinization (0.05% trypsin-EDTA) when reaching 90% confluence, and then replated. The medium was changed every 3-4 days.
Adipose Tissue
Subcutaneous adipose tissue was cut into fine pieces and digested with 1 mg/mL collagenase IA (Sigma) for 90 minutes at 37°C while shaking. The released cells were centrifuged for 15 minutes at 400g, washed with PBS twice and filtered through a 70 µm mesh. To separate MSCs from adipocytes, the cell suspension was subjected to two additional centrifugation steps at 800g. Pelleted MSCs were resuspended in lysis buffer (BD) to lyse and remove red blood cells. The residual cells were eventually cultured as described for BM-derived cells.
At least 3 independent isolations were performed for each isolation protocol.
Animal care and hind-limb ischemia
Animal care and treatment were conducted in conformity with institutional guidelines, in compliance with national and international laws and policies (European Economic Community Council Directive 86/609, OJL 358, December 12th, 1987 and UE2010763) after institutional review board approval. Mice (6-week-old female C57/BL6) were anesthetized using xylazine (40 mg/kg) and ketamine (100 mg/kg), prior to ligation and removal of the entire left femoral artery. The following day, mice were randomly divided into 4 groups (n>10) and injected intramuscularly with AT-, BM-, iBM-MSCs or medium as control. Each animal received 5x10 4 (passage 3-5) cells in its left tibialis anterior muscle and 1,5x10 5 cells in its left gastrocnemious muscle (final volume: 50 µl and 150 µl, respectively). Mice were repeatedly monitored for limb function, according to the parameters described in Table S2 . At the end of the experiments (day 21), the injected muscles were harvested, embedded in paraffin and processed for histological analysis.
The tibialis muscles were analyzed on transversal sections, while the gastrocnemious muscles on longitudinal sections.
For cell fate and retention experiments, MSCs were labeled with DiI dye (Invitrogen) and administered as previously described into the left tibialis anterior and gastrocnemious muscles the day after CLI (n= 6 per group).
Planar Scintigraphy
Planar Scintigraphy was performed prior to surgery (baseline, shown for 8 representative animals in Figure S4 ), on day 1 (immediately before MSC injection), as well as on days 7
and 14 (n=8 per group). Functional images of the mouse hind limbs were acquired after the injection of 37 MBq (1 µL) of 99mTc tetrofosmin (Myoview®, GE Healthcare) into the jugular vein (small pinhole collimator hole: 4 mm; frame-acquisition time 10 min; zoom acquisition 3.2). Quantitative analysis was made by manually drawing an oval region of interest (ROI) first on the ischemic hind limb and then symmetrically applying the same ROI to the contralateral limb. ROI was demarcated paying attention to avoid abdominal radioactivity and to include limb extremities. Perfusion data at each time point were expressed as a right/left ratio to overcome inter-animal variability and eventually normalized to the perfusion measured at day1 to overcome possible differences due to the severity of muscle ischemia.
Flow cytometry
Cells surface antigens were analyzed by flow cytometry using a BD FACSCalibur. MSCs Table S1 and Figure S1B .
Colony Forming Unit assay (CFU) and cell proliferation assay
For the proliferation assay murine AT-, iBM-, BM-MSCs (1x10 5 cells at passage 2) were plated in 6-multiwell plates and counted daily for four days. For CFU assay, MSCs (250 cells at passage 2) were plated in a 6-multiwell plate; after 10 days of culture, cells were stained with Crystal Violet and the number of colonies was counted manually. The experiments were performed in triplicate and results expressed as mean±SEM.
Differentiation assays
Differentiation was performed on cells at passage 3 using Adipolife, OsteoLife and
ChondroLife complete medium, respectively (all from LifeLine Cell Technologies). Oil Red, Alizarin Red, and Alcian Blue (LifeLine Cell Technologies) staining for adipocytes, osteocytes, and chondrocytes, were performed according to the manufacturer protocols.
Histology and immunofluorescence
Cultured MSCs were immunostained for CD44 (Abcam, 1:100) and CD105 (R&D system, 1:100), followed by goat anti-rabbit or donkey anti-goat AlexaFluor 594 (Molecular Probes, 1:1000). All images were acquired using a fluorescence microscope (Leica Microsystems), equipped with a charge-coupled device camera. In all experiments, exposure and picture processing were applied equally to sample sections and controls (isotype or primary antibody present).
Muscle sections were stained with hematoxylin-eosin to perform morphometric analysis of tissue damage, cell infiltration (on longitudinal section), and fiber regeneration (on transversal section) by acquiring at least 10 images per mouse and using NIH ImageJ To track cell engraftment in vivo, MSCs were labeled with DiI (Invitrogen) prior to injection.
Injected muscles were snap frozen and cryosections were stained for 2 hours at RT with FITC-LECTIN. Quantification of retained cells was performed using the ImageJ software (9 slices every 50 µm per muscle, 6 fields per section). To track cell differentiation in vivo, muscles at 21 days were stained with rat polyclonal anti-CD31 (1:100, BD Pharmingen) or
Cy3-conjugated α-SMA (1:200, Sigma) antibodies, followed by goat anti-mouse AlexaFluor 488 (1:500, Molecular Probe) or goat anti-rat AlexaFluor 488 antibody (1:500, Invitrogen), respectively.
Real-Time PCR
Total RNA was extracted from MSCs isolated according to the three experimental procedures (n=3 each) using TRIzol reagent (Invitrogen) according to manufacturer instructions, treated with DNase I (Roche) and reverse transcribed using hexameric random primers. The cDNA was then used as a template for real-time PCR amplification to detect the expression levels of the murine genes listed in Table S3 . The housekeeping gene Gapdh was used to normalize the results. All the amplifications were performed on a Bio-Rad Real-time thermal cycler CFX96 using TaqMan probes (Applied Biosystem).
Migration assay
Migration assays were performed using 8 µm pore Transwell permeable supports (Costar, 
Apoptosis assay
MSC apoptosis was induced in 6-multiwell plates adding 500 µM of hydrogen peroxide (H 2 O 2 ). The Annexin V-FITC Apoptosis Detection Kit (Roche) was used to quantify the number of apoptotic cells by flow cytometry, according to manufacturer instructions.
Apoptosis induced by doxorubicin (2 µM for 12 hours) was evaluated using Caspase-Glo 3/7 Assay Systems (Promega) in 96-multiwell plates, according to manufacturer instructions and analyzed by the EnVision multilabel reader (Perkin Elmer). All experiments were performed in triplicate and data, normalized over untreated cells, are presented as mean±SEM.
Senescence assay
Senescence associated-β galactosidase (SA-β gal) was evaluated on cells at passages 4 and 12, kept in culture for 5 days. Cells were washed with PBS, fixed for 10 minutes in 4%
PFA, washed in PBS and incubated at 37°C with senescence X gal stain solution (1 mg Xgalactose; 40 mM citric acid/sodium phosphate at pH 6; 5mM potassium ferricyanide; 150mM NaCl; 2mM MgCl 2 ). Images of stained cells were acquired after 12 hours.
Conditioned medium preparation
MSCs (1x10 6 cells at passage 4) were plated in 6 cm 2 dishes and incubated in complete medium for 1 day. Cells were then washed with PBS and the medium was replaced with 1 ml of serum free medium. Media were collected after 24 hours, concentrated using the Amicon Ultra 0,5 Centrifugal Devices (cut-off 3 kDa; Millipore) and filtered through a 20 µm filter. The concentrated conditioned media (CM) were frozen and stored at -80°C. Three doses of CM corresponding to 2x10 5 MSCs were injected in the tibialis anterior and in the gastrocnemius muscles of C57/BL6 mice at day 1, 3, 7 after surgery (n=6 animals per group). Animals were followed for 21 days for functional and histological evaluation.
Western Blot
To quantify the levels of PDGF-β secreted by the three MSC populations, CM was collected from the same number of AT-, iBM-and BM-MSCs. Samples were resolved by 10% SDS-PAGE and transferred to PVDF membranes (GE Healthcare). Immunoblots were blocked in 5% bovine serum albumin in TBS-Tween (50 mM Tris-HCl, pH 7.4; 200 mM NaCl; and 0.1% Tween 20), incubated O/N at 4 o C with primary rabbit polyclonal anti-PDGF-β antibody (sc-7878 Santa Cruz) and then with anti-rabbit HPR-conjugated secondary antibodies for 1 hour at room temperature. Proteins were detected by enhanced chemiluminescence (GE Healthcare). CM obtained after transfection of a Pdgf-β plasmid was used a positive control for the antibody. Band intensity was analyzed using the ImageJ software.
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